Alberta Investment Management Corp Has $6.95 Million Position in Encompass Health Co. (NYSE:EHC)
Table of Contents
Alberta Investment Management Corp trimmed its stake in Encompass Health Co. (NYSE:EHC – Free Report) by 17.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 104,159 shares of the company’s stock after selling 22,046 shares during the period. Alberta Investment Management Corp owned about 0.10% of Encompass Health worth $6,949,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. TFO Wealth Partners LLC lifted its position in Encompass Health by 39,783.3% during the 4th quarter. TFO Wealth Partners LLC now owns 2,393 shares of the company’s stock worth $160,000 after buying an additional 2,387 shares in the last quarter. Treasurer of the State of North Carolina grew its stake in shares of Encompass Health by 68.5% during the fourth quarter. Treasurer of the State of North Carolina now owns 81,452 shares of the company’s stock valued at $5,434,000 after purchasing an additional 33,113 shares during the last quarter. Allianz Asset Management GmbH increased its holdings in shares of Encompass Health by 701.7% in the fourth quarter. Allianz Asset Management GmbH now owns 192,350 shares of the company’s stock valued at $12,834,000 after purchasing an additional 168,358 shares in the last quarter. TD Asset Management Inc raised its position in Encompass Health by 239.6% in the 4th quarter. TD Asset Management Inc now owns 1,969,186 shares of the company’s stock worth $131,384,000 after purchasing an additional 1,389,275 shares during the last quarter. Finally, Parallel Advisors LLC lifted its holdings in Encompass Health by 192.3% during the 4th quarter. Parallel Advisors LLC now owns 573 shares of the company’s stock worth $38,000 after buying an additional 377 shares in the last quarter. 97.25% of the stock is owned by institutional investors.
Insider Activity
In related news, CEO Mark J. Tarr sold 44,976 shares of the business’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the transaction, the chief executive officer now owns 554,098 shares in the company, valued at approximately $46,139,740.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Elissa Joy Charbonneau sold 10,000 shares of the stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $85.02, for a total value of $850,200.00. Following the completion of the sale, the insider now directly owns 18,594 shares of the company’s stock, valued at $1,580,861.88. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Mark J. Tarr sold 44,976 shares of the company’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the completion of the sale, the chief executive officer now owns 554,098 shares of the company’s stock, valued at approximately $46,139,740.46. The disclosure for this sale can be found here. In the last three months, insiders have sold 69,519 shares of company stock valued at $5,816,091. 2.10% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Several equities analysts have weighed in on the company. Truist Financial increased their target price on shares of Encompass Health from $82.00 to $86.00 and gave the stock a “buy” rating in a report on Friday, February 9th. William Blair reaffirmed an “outperform” rating on shares of Encompass Health in a research report on Wednesday, February 7th. Raymond James reiterated a “strong-buy” rating and issued a $95.00 price objective (up from $85.00) on shares of Encompass Health in a research report on Friday, April 26th. Mizuho lifted their price target on shares of Encompass Health from $93.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Finally, Barclays increased their price objective on shares of Encompass Health from $101.00 to $108.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Encompass Health has a consensus rating of “Buy” and an average target price of $92.00.
Read Our Latest Stock Analysis on EHC
Encompass Health Stock Performance
NYSE EHC traded up $0.78 on Friday, reaching $86.39. The stock had a trading volume of 545,749 shares, compared to its average volume of 464,768. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.37 and a quick ratio of 1.37. The firm has a fifty day moving average of $83.02 and a two-hundred day moving average of $74.74. Encompass Health Co. has a 1-year low of $57.55 and a 1-year high of $87.94. The company has a market cap of $8.70 billion, a P/E ratio of 23.35, a price-to-earnings-growth ratio of 1.33 and a beta of 0.92.
Encompass Health (NYSE:EHC – Get Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.19. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The company had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.27 billion. During the same quarter last year, the business earned $0.88 earnings per share. Encompass Health’s revenue was up 13.4% on a year-over-year basis. On average, equities research analysts anticipate that Encompass Health Co. will post 4.1 EPS for the current year.
Encompass Health Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Monday, July 1st will be given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend is Monday, July 1st. Encompass Health’s dividend payout ratio is currently 16.22%.
About Encompass Health
(Free Report)
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Encompass Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Encompass Health wasn’t on the list.
While Encompass Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You’d need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.